Secondary bacterial pathogen infection has been demonstrated to aggravate COVID-19 clinical outcomes. Bacterial infections acquired during a hospital stay are likely resistant to several antimicrobial medicines, making COVID-19 patient management difficult. As a result, it is believed that aerosolized colistin might be a viable choice for treating secondary bacterial infections caused by gram-negative resistant strains in individuals who also have COVID-19 infection.

Inclusion Criteria:

• Covid-19 patients with secondary gram-negative bacterial infections

Exclusion Criteria:

• Patients with resistant bacterial strains to polymyxins
• patients less than 18 years